Senior
Leadership
Team
Andrew Obenshain
Chief Executive Officer
Andrew brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. He was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully secured multiple regulatory approvals across major geographies.
Prior to bluebird, Andrew held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics.
He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management
Nazira Amra, MD
Chief Commercial Strategy Officer
Nazira is a physician and senior commercial executive with more than 25 years of experience across global pharmaceutical, biotechnology, and emerging techbio companies. She brings deep expertise in cardiometabolic disease, including MASH, and has led multiple global product launches.
Nazira previously held multiple senior leadership roles at Sanofi, where she led global franchises and regional operations, before transitioning to biotechnology in 2015. After leading MASH launch readiness at Intercept Pharmaceuticals, she transitioned to commercial strategy at Exscientia, an AI-driven drug discovery company, ahead of its IPO, and has since advised life sciences companies on strategy, financing, and organizational design.
She holds a BSc (Honors) in Biology and an M.D. from McGill University, as well as an M.B.A from INSEAD.
Jason Campagna, MD, PhD,
President of R&D and Chief Medical Officer
Jason brings more than 20 years of leadership experience in early- and late-stage clinical development across leading biopharmaceutical companies. Most recently, he served as Chief Medical Officer at Q32 Bio, where he oversaw clinical strategy and development.
Previously, Jason held multiple leadership roles at Intercept Pharmaceuticals, including Head of the Global MASH Program, which led to the first-ever NDA submission to the FDA for a therapy targeting MASH. He later served as Chief Medical Officer with responsibility for the company’s PBC franchise, global MASH program, and broader pipeline strategy.
Before joining Intercept, Jason held positions of increasing responsibility at The Medicines Company, including as Senior Vice President and Health Science Lead for Surgery and Perioperative Care.
Pascaline Clerc, PhD
EVP, External and Corporate Affairs
Pascaline brings more than 20 years of leadership experience spanning biotechnology, government, academia, and non-profit organizations. Her background combines scientific training with deep expertise in public policy, legislative affairs, advocacy, and strategic communications across the United States and Europe.
She has developed particular expertise in MASH and in stakeholder engagement at the intersection of science, healthcare policy, and public affairs. Prior to joining Inventiva, Pascaline served as Vice President, External Affairs at Genfit, where she led global public policy and patient advocacy initiatives supporting disease awareness, stakeholder engagement, and corporate positioning in metabolic and liver diseases.
Earlier in her career, she held policy and legislative affairs roles in Washington, D.C., engaging with federal institutions, regulatory agencies, and multi-stakeholder coalitions on healthcare, biomedical research, and regulatory policy matters.
She was also selected for a Science & Technology Policy Fellowship with the American Association for the Advancement of Science (AAAS). Pascaline holds a Master of Science in Biochemistry, Cellular & Molecular Biology and a Ph.D. in Cellular Biology from Université Grenoble Alpes, France.
Consult Pascaline’s profileSusan Coles
Chief Legal Officer
Susan is an experienced legal executive with more than 25 years of expertise in international collaborations, corporate governance, licensing, and commercial transactions, particularly in the life sciences sector.
She previously served as General Counsel of Vivet Therapeutics from 2017 to 2025 and of Stallergenes from 2014 to 2017. Susan also previously served as General Counsel of Inventiva from 2012 to 2014 and again from 2019 to 2021. Earlier in her career, she was Senior Counsel responsible for Licensing and Acquisitions at Laboratoires Fournier and subsequently Solvay Pharmaceuticals following its acquisition of Fournier.
Susan has served on the Supervisory Board of TME Pharma since 2021. She holds a B.A. in Psychology from the University of British Columbia and an LL.B. from the University of Toronto. She is an attorney of the Bar of Ontario and the New York Bar.
Pamela Herbster
Chief People Officer
Pamela brings more than 25 years of leadership experience in human resources, organizational transformation, and business operations across the biopharmaceutical and healthcare sectors. She joins Inventiva from Sage Therapeutics, where she served as Senior Vice President, Chief People & Experience Officer and played a key role in supporting the company’s growth, talent strategy, and organizational development through its acquisition by Supernus Pharmaceuticals.
Prior to Sage, Pamela held a global leadership role at EMD Serono / Merck KGaA, where she oversaw Regulatory Affairs, Business Development, and Alliance Management, and also served as U.S. Site Head for Research & Development. Earlier in her career, she spent six years at Biogen in business partner roles of increasing responsibility, supporting multiple functions during periods of growth and transformation.
Pamela began her career within the Johnson & Johnson family of companies, where she developed broad cross-functional experience across the healthcare industry. Her background includes mergers and acquisitions, divestitures, talent strategy, organizational effectiveness, and product launches across consumer health, medical devices, and pharmaceuticals.
She holds a B.S. in Industrial and Labor Relations from Cornell University and an M.B.A. from the Anderson School of Management at UCLA.
Axel-Sven Malkomes
Chief Financial Officer
Axel-Sven brings more than 30 years of experience in finance, capital markets, M&A, and corporate leadership across the life sciences sector. Most recently, he served as Chief Financial Officer of CureVac N.V., where he played a key role in the company’s transformation and in its acquisition by BioNTech.
Previously, he served as CFO of Cardior Pharmaceuticals, where he supported major financing and strategic transactions leading to its acquisition by Novo Nordisk. He also served as CFO/CBO of Medigene AG, where he helped reshape the company strategically and financially.
Earlier in his career, Axel-Sven held senior healthcare investment banking roles at Barclays and Société Générale and private equity leadership positions at 3i Group plc. He also held senior corporate and operational leadership roles at Merck KGaA.
He holds a degree in Business Administration from Otto-Friedrich University Bamberg and completed executive programs at INSEAD, Kellogg School of Management, and HKUST.
Martine Zimmermann, PharmD
EVP, Regulatory Affairs and Quality Assurance
Martine brings over 30 years of combined experience in R&D and global regulatory strategy. Most recently, she served as Senior Vice President, Head of Regulatory Affairs at Ipsen, where she successfully led the team that secured regulatory approvals for two liver disease therapies, including a dual PPARα/δ agonist for the treatment of primary biliary cholangitis.
Previously, Martine served as Senior Vice President and Head of Global Regulatory Affairs & Quality at Alexion Pharmaceuticals (now AstraZeneca Rare Disease) where she played a key role in advancing multiple orphan medicinal products globally. Earlier in her career, she held R&D and regulatory leadership positions at Aventis (now Sanofi), Servier, and H. Lundbeck A/S.
A recognized advocate for diversity, equity, inclusion, and belonging, Martine was honored as a Luminary by the Healthcare Businesswomen’s Association in 2020. She also served as an executive sponsor for Alexion’s flagship Women in Leadership (WIL) employee resource group. Martine earned her Doctor of Pharmacy (PharmD) from the University Louis Pasteur in Strasbourg, France.
